Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Zhao, Wei  [Clear All Filters]
Journal Article
Yuan Q, Wang L, Huang J, Zhao W, Wu J. metabolizable branched poly(ester amide) based on inositol and amino acids as a drug nanocarrier for cancer therapy. Biomater Sci. 2021;9(19):6555-6567.
Han S, Dong K, Shen M, Wang X, Jiang W, Zhao W, Xu D. Observation and mechanism study of bladder wound healing after transurethral holmium laser resection of bladder tumor. Lasers Med Sci. 2019.
Lu B, Zou C, Yang M, He Y, He J, Zhang C, Chen S, Yu J, Liu KYun, Cao Q, et al. Pharmacological Inhibition of Core Regulatory Circuitry Liquid-liquid Phase Separation Suppresses Metastasis and Chemoresistance in Osteosarcoma. Adv Sci (Weinh). 2021:e2101895.
Feng L, Zhao W, Fan Y, Yuan C, Zhang X. RNA N6-methyladenosine demethylase FTO inhibits glucocorticoid-induced osteoblast differentiation and function in bone marrow mesenchymal stem cells. J Cell Biochem. 2023.
Zhao Y, Zhao W, Lim YChieh, Liu T. Salinomycin-loaded gold nanoparticles for treating cancer stem cells by ferroptosis-induced cell death. Mol Pharm. 2019.
Lei A, Yu H, Lu S, Lu H, Ding X, Tan T, Zhang H, Zhu M, Tian L, Wang X, et al. A second-generation M1-polarized CAR macrophage with antitumor efficacy. Nat Immunol. 2023.
Yang M, Yang C, Ma D, Li Z, Zhao W, Yang D. Single-cell analysis reveals cellular reprogramming in advanced colon cancer following FOLFOX-bevacizumab treatment. Front Oncol. 2023;13:1219642.
Zhao W, Lei A, Tian L, Wang X, Correia C, Weiskittel T, Li H, Trounson A, Fu Q, Yao K, et al. Strategies for Genetically Engineering Hypoimmunogenic Universal Pluripotent Stem Cells. iScience. 2020;23(6):101162.
Fang Y, Hu X, Zhao W, Pan J, Wang D, Bu K, Mao Y, Chu S, Liu P, Zhai T, et al. Structural Determination and Nonlinear Optical Properties of New 1T'''-Type MoS Compound. J Am Chem Soc. 2019.
Wu X, Li J-H, Xu L, Li Y-X, Zhu X-X, Wang X-Y, Wu XM, Zhao W, Ni X, Yin X-Y. SUMO specific peptidase 3 halts pancreatic ductal adenocarcinoma metastasis via deSUMOylating DKC1. Cell Death Differ. 2023.
Huang C-S, Zhu Y-Q, Xu Q-C, Chen S, Huang Y, Zhao G, Ni X, Liu B, Zhao W, Yin X-Y. YTHDF2 promotes intrahepatic cholangiocarcinoma progression and desensitises cisplatin treatment by increasing CDKN1B mRNA degradation. Clin Transl Med. 2022;12(6):e848.
Huang C, Li Y, Zhao W, Zhang A, Lu C, Wang Z, Liu L. α2δ1 may be a potential marker for tumor stem cell in laryngeal squamous cell carcinoma. Cancer Biomark. 2018.

Pages